Skip to main content
Clinical Trials/ACTRN12622001166763
ACTRN12622001166763
Completed
未知

Does anterior cruciate ligament (ACL) injury impair the molecular pathways responsible for building muscle?

Assoc Prof David Opar0 sites12 target enrollmentAugust 24, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Anterior Cruciate Ligament injury
Sponsor
Assoc Prof David Opar
Enrollment
12
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 24, 2022
End Date
September 30, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Assoc Prof David Opar

Eligibility Criteria

Inclusion Criteria

  • 1\.Male or female
  • 2\.Aged between 18 to 35 years
  • 3\.One leg sustained an ACL injury within the last 5\-years, but can safely complete lower limb strength training
  • 4\.BMI 18\.5\-29\.9m2

Exclusion Criteria

  • 1\.Any lower limb injury in the past 24\-months that influences the quadriceps responses to exercise (e.g. muscle strain)
  • 2\.Known cardiovascular disease or diabetes
  • 3\.Known bleeding disorder (i.e. hemophilia A \[factor VIII deficiency], hemophilia B \[factor IX deficiency], von Willebrand disease, or other rare factor deficiencies including I, II, V, VII, X, XI, XII and XIII)
  • 4\.Major or chronic illness that impairs mobility or eating/digestion
  • 5\.Taking prescription medications (i.e. beta\-blockers, anti\-arrhythmic drugs, statins, insulin sensitising drugs, or drugs that increase the risk of bleeding \[i.e. anticoagulants, antiplatelets, novel oral anticoagulants \[NOAs], nonsteroidal anti\-inflammatory drugs \[NSAIDs], selective norepinephrine reuptake inhibitors \[SNRI], or selective serotonin reuptake inhibitors \[SSRIs])

Outcomes

Primary Outcomes

Not specified

Similar Trials